George Church, PhD

George Church is Professor of Genetics at Harvard Medical School and Director of PersonalGenomes.org, which provides the world’s only open-access information on human genomic, environmental, and trait data (GET Conference). His 1984 Harvard PhD included the first methods for direct genome sequencing, molecular multiplexing and barcoding. These led to the first genome sequence (pathogen, Helicobacter pylori) in 1994. His innovations have contributed to nearly all “next generation” DNA sequencing methods and companies (CGI-BGI, Life, Illumina, Nanopore). This, plus his lab’s work on chip-DNA-synthesis, gene editing and stem cell engineering, resulted in founding additional application-based companies spanning fields of medical diagnostics (Knome/PierianDx, Alacris, Nebula, Veritas) and synthetic biology/therapeutics (AbVitro/Juno, Gen9/enEvolv/Zymergen/Warpdrive/Gingko, Editas, Egenesis). He has also pioneered new privacy, biosafety, ELSI, environmental, and biosecurity policies. He was director of an IARPA BRAIN Project and three NIH Centers for Excellence in Genomic Science (2004-2020). His honors include election to NAS and NAE and Franklin Bower Laureate for Achievement in Science. He has coauthored 716 papers, 156 patent publications, and a book (Regenesis).

Adam Koppel, MD, PhD, MBA

Adam M. Koppel is a Partner at Bain Capital Life Sciences. He initially joined Bain Capital Public Equity in 2003, where he was a leader within the healthcare sector until 2014. From 2014 to 2016, Dr. Koppel was EVP of Corporate Development and Chief Strategy Officer at Biogen. Prior to joining Bain Capital Public Equity in 2003, Dr. Koppel was an associate principal at McKinsey & Co. in New Jersey, where he served a variety of healthcare companies.

Dr. Koppel sits on the Board of Directors of Areteia Therapeutics, Cardurion Pharmaceuticals and Kailera Therapeutics and previously served on the Board of Directors of Aptinyx (NASD: APTX), Cerevel Therapeutics (NASD: CERE), Dicerna Pharmaceuticals (NASD: DRNA), Foghorn Therapeutics (NASD: FHTX), PTC Therapeutics (NASD: PTCT), Solid Biosciences (NASD: SLDB), Trevena, Inc (NASD: TRVN), and ViaCyte Inc.

Dr. Koppel is currently chairman of the Board of Trustees of the Boston Museum of Science, and also serves on the boards of the Newton-Wellesley Hospital, CJP Boston and The William Penn Charter School in Philadelphia. He sits on the Investment Committee of the Society for Neuroscience, co-chairs the Harvard Medical School Discovery Council, and serves on the Mass General Brigham Innovation Growth Board.

Dr. Koppel received an MD and PhD in Neuroscience from the University of Pennsylvania School of Medicine. He also received an MBA from The Wharton School at the University of Pennsylvania, where he was a Palmer Scholar. He graduated magna cum laude from Harvard University with an AB and AM in History and Science.

John Lepore, MD

John Lepore joined Flagship Pioneering in 2023 as CEO-Partner and Chief Executive Officer of ProFound Therapeutics.

John was previously Senior Vice President, Head of Research at GSK where he led a large organization of scientists and physicians focused on leveraging the science of immunology, human genetics and genomics, and advanced technologies to identify novel drug targets, discover new therapeutic molecules, and demonstrate proof of mechanism in clinical studies.

During his 17-year tenure at GSK, he held roles of increasing responsibility including VP of Clinical Pharmacology and Discovery Medicine, VP and Head of the Heart Failure Discovery Performance Unit, SVP and Head of the Metabolic Pathways and Cardiovascular Therapeutic Area Unit, and SVP R&D Pipeline responsible for end-to-end R&D activities across multiple therapeutic areas. He was also Interim Head of Business Development and played a key role in multiple preclinical and clinical deals to augment the GSK pipeline.

Before joining GSK, John was on the faculty of the Cardiovascular Medicine Division of the Department of Medicine at the University of Pennsylvania, where his lab investigated the transcriptional regulation of cardiovascular development, and he was attending physician on the academic cardiology service.

John received his B.S. in Biology from the University of Scranton and his medical degree from Harvard Medical School where he was a Howard Hughes Medical Institute Research Scholar. He subsequently trained in internal medicine and cardiology and served as Medical Chief Resident at Massachusetts General Hospital, with post-doctoral training at the Harvard School of Public Health.

John has been on the Board of Directors of ViiV Healthcare, the Altius Institute, and the Biotechnology Innovation Organization (BIO), the Scientific Advisory Boards of Medicxi Ventures and Hatteras Ventures, and the Innovation Growth Board of Mass General Brigham. At GSK, he chaired the Research Review Board and Research Investment Board responsible for capital allocation and project prioritization.

Todd Park

Todd Park is a leading American entrepreneur and government official. He served as Chief Technology Officer of the United States and technology advisor for U.S. President Barack Obama. He is the co-founder and executive chairman of Devoted Health. At the age of 24 he co-founded Athena Health a clinical management software used by 160,000 providers in the U.S. He also co-founded Castlight Health, a health navigation company named by the Wall Street Journal as the #1 venture-backed company in America for 2011.

Tanay Tandon

Tanay Tandon is the Founder and Chief Executive Officer of Commure, a $6 billion healthcare AI software platform powering daily workflows for over 250,000 clinicians across over 100 major health systems. Under his leadership, Commure has raised over $600 million from top-tier investors including General Catalyst, Sequoia Capital, Initialized, Y Combinator, and NVIDIA.